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Abstract
Canine leishmaniosis (CanL) due to Leishmania infantum is a chronic zoonotic systemic dis-
ease resulting from complex interactions between protozoa and the canine immune system.
Toll-like receptors (TLRs) are essential components of the innate immune system and facili-
tate the early detection of many infections. However, the role of TLRs in CanL remains
unknown and information describing TLR transcription during infection is extremely scarce.
The aim of this research project was to investigate the impact of L. infantum infection on
canine TLR transcription using a susceptible model. The objectives of this study were to eval-
uate transcription of TLRs 2, 3, 4 and 9 bymeans of quantitative reverse transcription poly-
merase chain reaction (qRT-PCR) in skin, spleen, lymph node and liver in the presence or
absence of experimental L. infantum infection in Beagle dogs. These findings were compared
with clinical and serological data, parasite densities in infected tissues and transcription of IL-
17, IL-22 and FoxP3 in different tissues in non-infected dogs (n = 10), and at six months (n =
24) and 15months (n = 7) post infection. Results revealed significant down regulation of tran-
scription with disease progression in lymph node samples for TLR3, TLR4, TLR9, IL-17, IL-22
and FoxP3. In spleen samples, significant down regulation of transcription was seen in TLR4
and IL-22 when both infected groups were compared with controls. In liver samples, down
regulation of transcription was evident with disease progression for IL-22. In the skin, upregu-
lation was seen only for TLR9 and FoxP3 in the early stages of infection. Subtle changes or
down regulation in TLR transcription, Th17 cytokines and FoxP3 are indicative of the silent
establishment of infection that Leishmania is renowned for. These observations provide new
insights about TLR transcription, Th17 cytokines and Foxp3 in the liver, spleen, lymph node
and skin in CanL and highlight possible markers of disease susceptibility in this model.
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Introduction
Leishmaniases are diseases caused by more than 20 species of protozoa within the genus Leish-
mania, following transmission by the bite of phlebotomine sand-flies. Both human and canine
leishmaniosis (CanL) are classed as neglected diseases and are endemic in the Mediterranean
Basin, the Middle East and tropical and sub-tropical regions of the world [1].
Leishmania infantum is the species most commonly associated with canine infections [2].
This infection in dogs can manifest as chronic subclinical infection, self-limiting disease or
severe illness and is largely prevalent in the Mediterranean Basin and Brazil [3]. In dogs, the
main effector mechanism involved in protective immunity is the activation of macrophages by
IFN-γ and TNF-α to eliminate intracellular amastigotes via the L-arginine nitric oxide pathway
[4]. Disease development is often correlated with increasing parasite burdens together with a
strong but inefficient humoral response [3].
In recent years, there has been plenty of evidence defining immune responses of specific
organs/tissues during Leishmania infection. However, much of this information derives from
murine models [5] and it is well established that findings from murine studies are inconsistent
when translated to the canine or human systems [6].
The innate immune responses associated with parasitic infections have been reported previ-
ously [7] and in more recent times toll-like receptors (TLRs) have been shown to play an
important role in leishmaniosis [8]. TLRs distinguish pathogen-associated molecular patterns
(PAMPs) derived from viruses, pathogenic bacteria, fungi and parasitic protozoa. TLRs are
type 1 integral membrane glycoproteins of tri-modular structure [9]. TLRs, with other innate
receptors, play a vital role in innate immune responses in addition to shaping adaptive immu-
nity [9]. While most studies have focused on bacterial and fungal pathogens, recent studies
have demonstrated that TLRs, in particular TLRs 2, 3, 4 and 9 may play a major role in recogni-
tion of protozoan pathogens such as Leishmania [8]. These TLRs appear to up-regulate and
activate pro-inflammatory responses in infected macrophages resulting in killing of the para-
site. These studies are based mainly on investigations into L.major infections in the mouse
model [8]. Leishmania major results in cutaneous leishmaniasis (CL) and the immune
responses associated with CL and CanL differ greatly. In contrast, there is a very limited body
of data available in the characteristics of innate immunity in dogs after infection with L.
infantum.
Th17 cells play a vital role in the protection of surfaces against many extracellular and fun-
gal pathogens but have also been implicated in the mediation of severe immune pathologies.
IL-17 is involved in the recruitment, migration and activation of neutrophils. [10]. IL-22 is also
produced by Th17 cells and to a lesser extent by natural killer and Th1 cells [10], and is particu-
larly involved in immunity at epithelial and mucosal surfaces [11]. IL-17 and IL-22 are inflam-
matory cytokines that play a protective role against intracellular parasites such as Leishmania
[12]. However, the role of IL-17 and IL-22 during Leishmania infection remains controversial
and poorly defined [13,14]. On the other hand, T regulatory lymphocytes (Tregs) have an
important role in suppression of host immunity in murine [15,16] and human leishmaniasis
[17,18] and probably also in CanL [19,20]. Tregs are characterised by the expression of CD4,
CD25, and the highly conserved transcription factor Forkhead box P3 (Foxp3) serving a pivotal
role in stabilising their regulatory properties [21]. However, Th17 cytokines [22] and the tran-
scription factor FoxP3 have been scarcely studied in CanL [19,20] and especially not in the vis-
ceral organs and require further investigations. In this study we aimed to evaluate the
transcription of TLR2, TLR3, TLR4, TLR9, as well as the cytokines IL-17 and IL-22 and tran-
scription factor FoxP3 in lymph node, skin, liver and spleen from L. infantum experimentally
infected and uninfected dogs. Previous studies have reported cytokine profiles associated with
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this disease [23,24], but there is a very limited amount of data describing TLR transcription
and FoxP3 in the visceral organs or skin of dogs. In particular, no studies to date have reported
TLR3 transcription in these organs and to our knowledge IL-17 and IL-22 have not been
reported in CanL.
Materials and Methods
Ethical statement
All procedures were approved by the local Ethical Review Committee of Zoetis, Olot, Spain
(formerly known as Fort Dodge Veterinaria S.A.) in compliance with national (Real Decreto
1201/2005) and European Union regulations (European Directive 86/609/CE) for projects
using animals for research purposes. The project license number assigned by the Ethics Com-
mittee that approved the study was number 132 and the permit number allocated by the Span-
ish Authorities was number 3303.
Study groups
Clinically healthy, non-infected control dogs. Liver, spleen, skin and popliteal lymph
node samples were obtained within fifteen minutes of euthanasia from 10 clinically healthy
Beagle dogs at Pfizer Ltd. (Sandwich, Kent, UK). Dogs were euthanized by intravenous over-
dose of barbiturate. All dogs were male and between 36 to 72 months of age at the time of nec-
ropsy and were previously used as control subjects in other studies. Tissue samples were cut
into 5mm3 pieces using sterile scissors and immediately transferred to cryo-tubes containing
RNA-later (Ambion, UK) and stored immediately according to manufacturer’s instructions
and indefinitely at -80°C until further use.
Experimentally infected dogs. Experimentally infected animals comprised of thirty one
six-month old, intact female beagles from which we obtained end-point tissue samples to per-
form the present study.
Dogs were housed in pens of six animals (13.2m2/pen) or seven animals (15.2m2/pen). Dogs
had direct contact with pen mates and with neighbouring pens and daily exercise in the facility
corridors. There was environmental enrichment in the form of toys (ropes, Kong toys stuffed
with treats and chew bones) and the inside of each cage had an elevated platform where dogs
could jump up onto or hide below. All dogs had previously received routine vaccinations and
were additionally treated with anthelmintic drugs. None of the dogs had detectable levels of
anti-Leishmania antibodies in serum determined by enzyme linked immune sorbent assay
(ELISA) [25]. Serum samples were also obtained for IgG, IgA and protein A ELISAs. ELISA’s
were performed as described previously [25] with some modifications and employed sonicated
crude total Leishmania antigen. Briefly, microtitre plates were coated with 2 μg of L. infantum
antigen per well. Polyclonal anti-dog immunoglobulin IgG, IgA (Bethyl Laboratories, Mont-
gomery, TX, USA) and Protein A (ProtA) (ImmunoPure1 Recomb1 Protein A, Pierce Rock-
ford, IL, USA) were all conjugated to horseradish peroxidase and were used individually as
secondary antibodies [26,27]. Protein A reacts with the Fc-region of Ig from many species
including canines [28]. Absorbance values were read at 492 nm in an automatic microELISA
reader (Anthos Labtec Instruments) and reactions were expressed in ELISA units (EU), which
was in relation to a known positive serum sample used as a calibrator and set at 100 EU. This
calibrator serum was always the same and included in all plates. Sera from 32 dogs living in a
non-endemic region for CanL were used to set up a cut-off for IgG and IgA. This was estab-
lished at 7.6 EU for IgG and 60 EU for IgA and 14 EU for Protein A. Any plate with an inter-
assay variation> 10% was discarded [27].
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Experimental infection and follow-up
Dogs were experimentally infected with a total dose of 2 x 108 L. infantum amastigotes
(MCAN/ES/92/BCN-83/MON-1, kindly provided by Dr Montserrat Gallego, Universitat de
Barcelona) via the intravenous route (i.v.). Briefly, L. infantum obtained from a naturally
infected dog which had not received any treatment was passaged through hamsters to retain
virulence. Amastigotes were isolated from spleens of infected hamsters and used immediately
for experimental infection. The removed spleen was homogenized in Schneider’s Drosophila
medium (Sigma, St Louis, MO, USA) supplemented with 20% foetal calf serum (Gibco, Paisley,
UK) and 25 μg/ML gentamicin (Sigma) and centrifuged at 500g for 10 minutes at 4°C. The
supernatant was washed three times and re-suspended in 0.9% physiological saline solution.
The number of viable parasites was determined after staining with crystal violet. Dogs were
infected by i.v. injection of 2 x 108 amastigotes in 1mL of saline solution. Following infection,
clinico-pathological findings associated with CanL were recorded monthly and scored as
detailed elsewhere [29]. Scores were added to give an overall clinico-pathological record for
each dog. Specifically, each animal underwent a complete physical examination monthly by the
same veterinarian and blood was collected for complete blood count and biochemistry analysis
including renal and hepatic function. Clinical findings including weight loss, cutaneous lesions
and lymphadenomegaly were scored from one to three and biochemical and haematological
findings were scored by assigning one point to each parameter with an abnormal value. To
minimise suffering of the dogs during infection, clinical end points for withdrawal were estab-
lished based on clinical signs of the disease and the veterinarian notified if any such observa-
tions were made. Such notifications included severe skin lesions, severe lameness, debilitating
diarrhoea, neurological signs or significant bleeding from any orifice.
Twenty four of the experimentally infected dogs were euthanized at 6 months post infection
(Group 1) and seven were euthanized at 15 months post infection (Group 2). There were no
deaths during the study period in any of the two groups. At necropsy, popliteal lymph node,
spleen, liver and ear skin samples were collected from all dogs and samples were snap-frozen in
liquid nitrogen. Dogs were anaesthetized with buprenorphine (dose: 6 mcg/kg) plus dexmede-
tomidine hydrochloride (dose: 12.5 mg/kg) or azepromacine (dose: 100 mg/kg) administered
intramuscularly. Approximately 30 minutes after anaesthesia they were euthanized with an
overdose (>200 mg/kg) of sodium pentobarbital (Dolethal1, Vetoquinol) intravenously.
Determination of parasite densities in infected tissues
DNA extractions from tissues were performed using a High Pure PCR Template Preparation
Kit (Roche, San Francisco, USA) according to manufacturers’ instructions. Leishmania DNA
in tissues was detected by quantitative real-time polymerase chain reaction (qRT-PCR) as pre-
viously described [30]. Briefly, PCR mastermix was made using Taqman1 Universal Master
Mix II (Applied Biosystems, USA) with Leishmania kinetoplast DNA specific primers designed
by Francino et al [30] (Leish1 forward primer 5’-AACTTTTCTGGTCCTCCGGGTAG’3’,
Leish2 reverse 5’-ACCCCCAGTTTCCCGCC-3’) and MGBProbe 5’-AAAATGGGTGCAG
AAAT-3’ (Applied Biosystems, UK). Assays were performed with a 25 μL final volume with
5 μL of sample DNA. The standard curve was established from Leishmania DNA extracted
from 1 × 107 parasites; 5 μL of serial dilutions, ranging from 103 to 10−3 parasites, was placed
into reaction tubes. The cycling conditions were; an incubation step at 50°C for 2 minutes, a
denaturation step at 95°C for 10 minutes followed by 40 cycles at 95°C for 15 s and 60°C for 1
minute. All PCR analyses were performed in a Step One Plus Real Time PCR System (Applied
Biosystems Laboratories, Foster City, CA, USA). Each standard, negative control and sample
were analysed in triplicate.
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RNA extraction, RNA integrity and cDNA generation
Tissue samples stored at -80°C in RNAlater (Ambion, Paisley, UK) or snap-frozen in liquid
nitrogen were thawed on ice and RNA extracted using an Ambion RiboPure Kit (Ambion)
according to the manufacturer’s instructions with a DNase digestion step included to remove
contaminating genomic DNA using TurboDNase (Ambion, Paisley, UK). RNA concentration
was determined by nanodrop using the Nanodrop ND-2000 spectrophotometer (Thermo-
Scientific, Wilmington, DE, USA) and samples were diluted in nuclease free water appropri-
ately to give a final concentration of 40 ng/μL per sample. The RNA integrity was determined
using an Agilent 2100 Bioanalyzer (Agilent Technologies, Waldbronn, Germany). All samples
included in this study had an RNA Integrity Number (RIN) value in excess of six.
cDNA was generated using an Oligo(dT)15 primer (Promega, Southampton, UK) and IM-
prom-II Reverse Transcriptase enzyme (Promega, Southampton, UK) according to the manu-
facturer’s instructions. cDNA was aliquoted and stored at -20°C.
Reference gene and target gene selection
Reference and target genes were as shown in Tables 1 and 2. The three most appropriate refer-
ence genes for each tissue were subsequently determined using geNorm normalization (Bioga-
zelle, Belgium). Selected genes were used to calculate the geometric mean from which absolute
quantification of target genes were performed.
Creation of PCR standard serial dilutions for qRT-PCR
PCR amplicons representing each test assay were purified and ligated into the cloning vector
pGEM1-TEasy (Promega, Southampton, UK) and then transformed using OneShot1 Top10
Chemically Competent Escherichia coli (Invitrogen) according to the manufacturer’s instruc-
tions. Plasmid extraction was performed using the PureYield Plasmid Miniprep System (Pro-
mega, Southampton, UK) according to the manufacturer’s instructions and used in
conventional PCR with the primers used to generate the original amplicon to confirm the pres-
ence of the insert. PCR mastermix was created by combining nuclease free water (NFW), Hi-
Spec additive (Bioline, Taunton, MA, USA), Immobuffer (Bioline, Taunton, MA, USA), MgCl2
(4.5 mM), dNTP mix (100 mM), specific primer mix (800 nM) and Immolase Taq (0.02 U/μlL
(Bioline, Taunton, MA, USA). 5 μL diluted cDNA was then added to 20 μL of mastermix to
give a final volume of 25 μL. Negative controls were performed by the addition of nuclease free
water instead of cDNA. PCR cycling conditions included enzyme activation (95°C) for seven
min followed by 35 cycles of denaturation at 94°C for 40 s, annealing at specific primer temper-
ature for 30 s and elongation at 72°C for 60 s. Finally, an extension step was performed at 72°C
for seven min.
Plasmids shown to have the specific insert were sent for Sanger sequencing (Source BioSci-
ence LifeSciences, UK) and subsequently aligned with the original gene sequence using CLC
Workbench version 6 (CLCBio, Denmark). The DNA concentration of eluted plasmids with
the required insert were determined by nanodrop (Nanodrop DN-2000, ThermoScientific,
Wilmington, DE, USA) then diluted with nuclease free water to a concentration of 1 x 107 cop-
ies/uL calculated using the plasmid nucleotide size and Avogadros constant, and a 10-fold
serial dilution series was created with a lowest concentration of 1 x 101 copies/uL.
qRT-PCR
Target cDNA numbers were quantified using real time PCR using Ssofast Evergreen Supermix
(Bio-Rad, CA, USA), target specific primers (Tables 1 and 2) and Cycler programs on the
TLR, Cytokine and FoxP3 Transcription in Experimental CanL
PLOS ONE | DOI:10.1371/journal.pone.0140325 October 14, 2015 5 / 19
CFX96 Real time detection system (Bio-Rad laboratories, CA, USA) were created according to
the manufacturer’s recommendations for optimized cycling conditions for RT-PCR. This com-
prised of an enzyme activation step at 95°C for 30 s (hot start), followed by 40 cycles of dena-
turation at 95°C for 5 s, annealing at specific primer annealing temperature (55–60°C, Tables 1
and 2) for 10 seconds and a melting curve analysis of 65–95°C with a plate read every 0.5°C at
Table 1. Primer sequences for selected reference genes.
Gene name
(abbreviation)
Primer sequence 5’– 3’ Product size
(base pairs)
Anneal.
temp (°C)
GenBank accession
number
Tissues employed Reference
Hypoxanthine
phosphoribosyl-
transferase 1
(HPRT1)
F: CACTGGGAAAACAATGCAGA 123 56 AY_283372 Liver [31]
R: ACAAAGTCAGGTTTATAGCCAACA Lymph node
Spleen
Hydroxymethyl-
bilane synthase
(HMBS)
F: TCACCATCGGAGCCATCT 112 57 XM_546491 Liver [31]
R: GTTCCCACCACGCTCTTCT Lymph node
Beta 2 –
microglobulin
(B2M)
F: ACGGAAAGGAGATGAAAGCA 99 56 XM_535458 Lymph node [31]
R: CCTGCTCATTGGGAGTGAA Spleen
Succinate
dehydrogenase
complex subunit A
(SDHA)
F: GCCTTGGATCTCTTGATGGA 92 56 XM_535807 Liver [31]
R: TTCTTGGCTCTTATGCGATG Skin
Glyceraldehyde– 3
—phosphate
dehydrogenase
(GAPDH)
F: GGAGAAAGCTGCCAAATATG 193 55 NM_001003142 Spleen [32]
R: ACCAGGAAATGAGCTTGACA Skin
HIRA interacting
protein 5 (HIRP5)
F: GGCTTTGAAGATGGCATTGT 127 56 XM_850340 Skin [33]
R: CACCCTCCACCTCTGGAATA
doi:10.1371/journal.pone.0140325.t001
Table 2. Primer sequences for target genes of interest.
Target gene(abbreviation) Primer sequence 5’– 3’ Product
size
(base pairs)
Annealing
temp (°C)
GenBank
accession
number
Reference
Toll-like receptor 2 (TLR2) F: AGTGGCCAGAAAAGCTGAAA 263 54.3 NM_001005264 [34]
R: ATCCAGTTGCTCCTTCGAGA
Toll-like receptor 3 (TLR3) F:GTCCAATTTCATTAAGGCCAAG 129 54 XM_540020.2 This study
R:TGTCACTTGCTCAGTCTCCTTT
Toll-like receptor 4 (TLR4) F: CAGCATTCCAGTTTGAAGCA 140 54.3 AB080363 This study
R: AAGACTTCGAGGCTGACCAA
Toll-like receptor 9 (TLR9) F: GCCTGGAGTACCTGCTCTTG 128 55 NM_001002998.1 This study
R: GTTACGGGCATGGTCACAG
Interleukin 17A (IL-17A) F: CCGATCTACCTCACCTTGGA 166 60 NM_001165878.1 [35]
R: TCGCAGAACCAGGATCTCTT
Interleukin 22 (IL-22) F: TCCAGCAGCCCTATATCACC 254 60 XM_538274.2 [35]
R: TTGGCTTAGCTTGTTGCTGA
Forkhead box P3 (FoxP3) F: GGCTCCTGCTGTATCGTAGC 179 55 NM_001168461.1 This study
R: CGCATGTTGTGGAATTTGAA
doi:10.1371/journal.pone.0140325.t002
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the end of the 40 cycles. Standard curves (ranging from 107 to 101 copies per μL) were gener-
ated from plasmids of known DNA concentration to allow absolute quantification of target
gene transcription. Each reaction was carried out in triplicate and the reaction efficacy was
determined for each gene using ten-fold dilutions (107 molecules/μl to 101 molecules/μl).
Nuclease free water was used in place of DNA in triplicate as the non-template control. Abso-
lute gene transcription was quantified by averaging triplicate quantities of each sample for all
test genes, following normalisation of the expression ratio of each using the geometric mean of
three reference genes.
Statistical analysis
SPSS (IBM, USA) statistical software (Version 21) was used for statistical analyses. Statistical
differences between groups were judged using the Kruskal-Wallis test with the Mann-Whitney
U- test used for post hoc comparison. Correlations between parasite densities in infected tis-
sues and clinical score data and all other parameters were performed using Spearman’s rank-
order correlation. Mann-Whitney U test was used to judge differences between groups, for
clinical data, serology and parasite density in infected tissues. R statistical software (Version
3.1.1) was used to construct heat maps for transcription level. Type I error rate, Alpha (α), was
set at 5%, and Bonferroni correction was used to evaluate significance for post-hoc
comparison.
Results
Clinical data, serology and parasite density in infected tissues
Control dogs from the UK were deemed clinically healthy and were not included in compari-
sons. Mann-Whitney U test revealed a significant increase (p<0.001) in clinical scores between
infected groups. Median (interquartile range [IQR]); Group 1 = 2.87 [0–0.73] and Group
2 = 22.55 [15.88–28.73].
Dogs from Group 1 presented with few or no clinical signs or clinico-pathological abnor-
malities with a mean clinical score of 2.67 and were seronegative or low seropositive. Dogs
from Group 2 presented clinical signs such as weight loss, alopecia, and exfoliative dermatitis,
lymphadenomegaly in addition to clinico-pathological abnormalities with a mean clinical
score of 21.58 and had high IgG and IgA antibody levels. Clinical scores significantly increased
between infected groups (p<0.001).
IgG and IgA serum levels measured by ELISA were both higher in Group 2 (300 [296.04–
311.75] and 119.38, [74.0–201.97], respectively, when compared with Group 1 (medi-
ans = 145.09 [23.02–281.29] and 79.21 [20.72–181.68]). This increase was statistically signifi-
cant for IgG (p<0.001) but not for IgA (p = 0.796). Mann-Whitney U test revealed a significant
increase (p<0.001) in protein A between the infected groups (Group 1 median = 95.64 [10.37–
174.71], Group 2 median = 1350.00 [600–1500.00]).
Parasite densities in infected tissues were expressed as the number of parasites per milligram
of tissue and not for the whole tissue as organs were not weighed. In the skin, the parasite den-
sity increased significantly between the two time points of infection [Median = 95.85 (1.60–
2455.10) and 1651 (3.50–47616.80) respectively, p = 0.038]. An increase in parasites/mg tissue
was also seen in the lymph node and a decrease noted in the liver, but these differences were
not significant. On the contrary, the parasite density in spleen samples was found to signifi-
cantly decrease with disease progression (p = 0.022). These findings are summarized in
Table 3.
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Absolute quantification of target gene transcription
Liver. Transcription of IL-22 was down regulated in the presence of L. infantum when the
controls were compared with each infected group. TLR2 transcription was up regulated with
disease progression and no differences were seen among groups in other cytokines, FoxP3 and
TLRs (Table 4).
Lymph node. Transcription was significantly down regulated for all genes of interest
(TLR2, TLR3, TLR4, TLR9, IL-17, IL-22 and FoxP3) with the exception of TLR9, when Group
1 were compared with the controls. Comparing Group 2 and the controls, down regulation was
observed for transcription of all genes of interest with the exception of TLR2 (Table 5).
Spleen. Significant differences in transcription were observed in the spleen samples for
TLR4, TLR9 and IL-22. Comparing Group 1 with the controls, transcription of TLR4 and IL-
22 was down regulated, whereas TLR9 was up regulated. Comparing Group 2 with the controls,
transcription of TLR4 and IL-22 was also down regulated. No differences were seen among
groups in IL-17, FoxP3 and TLRs (Table 6).
Skin. Transcription of TLR3 and TLR9 was down regulated in the later stages of infection
(comparing Groups 1 and 2). Transcription of TLR2 and TLR9, together with FoxP3, were all
up regulated in the earlier stages of infection when compared with the controls. No differences
were seen among groups in cytokines and other TLRs (Table 7).
Parasite densities in infected tissues correlated with all other parameters
Six months post infection. In the liver, there was moderate positive correlation between
parasite density and IgG serum levels (rs = 0.504, p = 0.012), and serum protein A (rs = 0.469,
Table 3. Median (range) and p-values for the parasite densities in infected tissues (parasites per mg/tissue) in both infected groups.
Tissue Group 1 (6 months post infection) Group 2 (15 months post infection) Group 1 vs Group 2
Spleen 21005.95 (0–110083.30) 2365.10 (17.10–39808.00) p = 0.022*
Liver 29450.70 (60.90–140482) 10668.30 (37.50–73515.10) p = 0.199
Lymph node 897.55 (0–22410.10) 1595 (16.60–5774.20) p = 0.695
Skin 95.85 (1.60–2455.10) 1651.70 (3.50–47616.80) p = 0.038*
(*) shows signiﬁcant differences (p = <0.05).
doi:10.1371/journal.pone.0140325.t003
Table 4. Median (range) and p-values for the transcription of target genes within liver samples.
Genes
(Liver)
Controls Group 1 (6 months post
infection)
Group 2 (15 months post
infection)
Controls vs
Group 1
Controls vs
Group 2
Group 1 vs
Group 2
TLR2 96.58 (84.42–
1392.73)
550.77 (128.43–903.51) 366.63 (201.42–892.36) p = 0.001* p = 0.007* p = 0.764
TLR3 239.34 (159.73–
3256.20)
298.42 (95.98–831.85) 214.97 (103.31–288.47) p = 0.809 p = 0.962 p = 0.695
TLR4 162.66 (118.09–
2348.42)
203.00 (47.76–400.73) 132.04 (90.40–303.30) p = 0.148 p = 0.315 p = 0.417
TLR9 556.32 (336.05–
7636.49)
1387.00 (192.72–7405.74) 497.47 (149.37–956.36) p = 0.196 p = 0.109 p = 0.502
IL-17 0.58 (0.27–6.98) 0.49 (0.08–1.99) 1.80 (1.63–17.4) p = 0.377 p = 0.571 p = 0.060
IL-22 6.63 (3.36–76.40) 0.46 (0.12–5.73) 2.83 (2.10–5.05) p<0.001* p = 0.033 p<0.001*
FoxP3 2.25 (2.05–32.54) 3.59 (0.81–11.61) 2.04 (1.35–36.79) p = 0.480 p = 0.232 p = 0.563
Signiﬁcant Bonferroni corrected p-values are highlighted bold (p< = α/3).
(*) p-value<0.016.
doi:10.1371/journal.pone.0140325.t004
TLR, Cytokine and FoxP3 Transcription in Experimental CanL
PLOS ONE | DOI:10.1371/journal.pone.0140325 October 14, 2015 8 / 19
p = 0.048). In the lymph node, moderate correlation with parasite density was revealed for
TLR9 transcription (rs = 0.427, p = 0.037), IgG serum levels (rs = 0.420, p = 0.041), serum pro-
tein A (rs = 0.460, p = 0.024) and clinical score (rs = 0.437, p = 0.037). In the spleen, serum IgG
(rs = 0.462, p = 0.023) and serum protein A (rs = 0.470, p = 0.020) were also positively corre-
lated with the parasite density. Lastly, in the skin, moderate to strong correlation was seen for
TLR3 transcription (rs = 0.556, p = 0.005), serum IgG (rs = 0.560, p = 0.004), serum protein A
(rs = 0.611, p = 0.002) and clinical score (rs = 0.598, p = 0.002) when correlated with parasite
density in infected skin. These correlations are all illustrated in the heat map shown in Fig 1A
together with all other correlations with parasite densities in infected tissues at six months post
infection.
Fifteen months post infection. At 15 months post infection, strong positive correlation
was revealed when parasite densities were correlated with FoxP3 transcription in both liver
Table 5. Median (range) and p-values for the transcription of target genes within lymph node samples.
Genes (Lymph
node)
Controls Group 1 (6 months
post infection)
Group 2 (15 months
post infection)
Controls vs
Group 1
Controls vs
Group 2
Group 1 vs
Group 2
TLR2 1221.20 (591.02–
2049.55)
567.61 (266.89–
4039.30)
1148.49 (946.55–
1644.48)
p = 0.001* p = 0.740 p = 0.001*
TLR3 2287.15 (1091.26–
5313.42)
310.27 (136.98–
2233.89)
146.77 (100.96–202.02) p<0.001* p<0.001* p = 0.001*
TLR4 1838.31 (1212.52–
3401.61)
349.76 (130.66–
1490.22)
284.16 (230.33–388.74) p<0.001* p <0.001* p = 0.872
TLR9 1565.95 (987.70–
3183.26)
2012.24 (665.90–
7213.90)
651.89 (341.12–943.30) p = 0.287 p<0.001* p <0.001*
IL-17 19.38 (0–55.43) 3.45 (0–22.95) 5.96 (0.71–7.01) p = 0.002* p = 0.005* p = 0.729
IL-22 67.88 (13.74–
1440.20)
4.95 (1.18–352.62) 1.87 (0.92–3.35) p<0.001* p <0.001* p = 0.002*
FoxP3 1029.74 (324.94–
2005.54)
197.26 (45.63–1248.18) 35.05 (20.14–55.11) p<0.001* p<0.001* p<0.001*
Signiﬁcant Bonferroni corrected p-values are highlighted bold (p< = α/3).
(*)p-value<0.016.
doi:10.1371/journal.pone.0140325.t005
Table 6. Median (range) and p-values for the transcription of target genes within spleen samples.
Genes
(Spleen)
Controls Group 1 (6 months post
infection)
Group 2 (15 months post
infection)
Controls vs
Group1
Controls vs
Group 2
Group 1 vs
Group 2
TLR2 3007.40 (1798.94–
3287.07)
2383.58 (1550.86–
4654.14)
2544.15 (1568.13–
5424.72)
p = 0.118 p = 0.417 p = 0.627
TLR3 1028.55 (517.35–
2312.03)
741.91 (157.04–2191.08) 367.96 (147.59–1120.88) p = 0.515 p = 0.088 p = 0.085
TLR4 3765.41 (2733.20–
4570.21)
1157.07 (483.38–
2924.33)
920.75 (445.67–1293.38) p = 0.002* p = 0.005* p = 0.182
TLR9 980.30 (560.20–
1222.08)
6866.13 (778.07–
119451.01)
2316.45 (395.51–
26120.09)
p<0.001* p = 0.364 p = 0.167
IL-17 1.46 (0.53–6.57) 2.27 (0.66–12.49) 1.84 (1.05–3.19) p = 0.393 p = 0.905 p = 0.273
IL-22 17.67 (11.68–35.42) 4.33 (0.94–22.27) 3.04 (0.18–20.26) p<0.001* p = 0.002* p = 0.661
FoxP3 43.73 (20.67–85.44) 62.78 (7.51–210.02) 39.94 (18.33–101.60) p = 0.222 p = 0.758 p = 0.139
Signiﬁcant Bonferroni corrected p-values are highlighted bold (p< = α/3).
(*)p-value<0.016.
doi:10.1371/journal.pone.0140325.t006
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and skin (rs = 0.821, p = 0.023 and rs = 0.860, p = 0.019, respectively) and also TLR4 transcrip-
tion in the lymph node (rs = 0.821, p = 0.023). These correlations are all illustrated in the heat
map shown in Fig 1B together with all other correlations with parasite densities in infected tis-
sues at 15 months post infection.
Table 7. Median (range) and p-values for the transcription of target genes within skin samples.
Genes
(Skin)
Controls Group 1 (6 months post
infection)
Group 2 (15 months post
infection)
Controls vs
Group 1
Controls vs
Group 2
Group 1 vs
Group 2
TLR2 67.93 (35.42–
100.44)
201.43 (107.29–316.82) 130.71 (129.19–198.86) p = 0.042 p = 0.171 p = 0.462
TLR3 277.62 (155.65–
399.59)
351.49(99.57–802.59) 125.43 (60.34–125.60) p = 0.728 p = 0.257 p = 0.038
TLR4 157.39 (120.51–
194.28)
172.54 (118.81–267.37) 103.71 (102.90–323.95) p = 0.262 p = 0.762 p = 0.940
TLR9 307.64 (214.71–
400.57)
1152.08 (509.62–1625.92) 174.57 (73.13–229.63) p = 0.007* p = 1.000 p = 0.044
IL-17 0.43 (0.23–0.64) 0.98 (0.31–9.06) 2.70 (0.98–4.12) p = 0.218 p = 0.200 p = 0.282
IL-22 9.57(2.15–16.99) 5.01 (1.91–9.02) 2.51 (0.28–5.92) p = 0.924 p = 0.171 p = 0.093
FoxP3 1.07 (0.82–1.33) 11.06 (1.53–21.54) 6.50 (1.73–8.93) p = 0.019^ p = 0.019^ p = 0.550
Signiﬁcant Bonferroni corrected p-values are highlighted bold (p< = α/3).
(*)p-value<0.016.
(^) indicates marginal signiﬁcance.
doi:10.1371/journal.pone.0140325.t007
Fig 1. Heat maps illustrating the positive (red) and negative (blue) correlation values between parasite densities at six months post infection (a)
and fifteenmonths post infection (b) in liver, lymph node, spleen and skin with transcription from genes of interest, serological parameters and
clinical scores.
doi:10.1371/journal.pone.0140325.g001
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Clinical score correlation with all other parameters
Six months post infection. There was strong positive correlation between clinical score
and IgG serum levels (rs = 0.623, p = 0.001), and serum Protein A (rs = 0.636, p = 0.001). In the
lymph node, there was a moderate correlation between clinical score and parasite density (rs =
0.437, p = 0.037). In the spleen, TLR4 transcription (rs = 0.483, p = 0.017) and IL-17 transcrip-
tion (rs = 0.499, p = 0.013) were also positively correlated with the parasite density. Lastly, in
the skin, moderate to strong correlation was seen for TLR3 transcription (rs = 0.447, p = 0.029),
and parasite density (rs = 0.598, p = 0.002) when correlated with clinical score. These correla-
tions are all illustrated in the heat map shown in Fig 2A together with all other correlations
with clinical score at six months post infection.
Fifteen months post infection. At 15 months post infection, strong positive correlation
was revealed in the skin for both IL-17 and FoxP3 transcription (rs = 1, p<0.001 in both
instances). These correlations are all illustrated in the heat map shown in Fig 2B together with
all other correlations with clinical score at 15 months post infection.
Discussion
The impact of Leishmania sp. infection on toll-like receptors has mainly been studied in
murine and human models [36] [37] [38] [39] [40]. To date, there is a limited amount of infor-
mation about the role that these receptors play in CanL [19,41,42]. This study aimed to investi-
gate the association between L. infantum infection and transcription of TLRs 2, 3, 4 and 9 in
the liver, spleen, lymph node and skin of dogs.
Fig 2. Heat maps illustrating the positive (red) and negative (blue) correlation values between clinical score at six months post infection (a) and
fifteen months post infection (b) in liver, lymph node, spleen and skin with transcription from genes of interest, serological parameters and
parasite densities.
doi:10.1371/journal.pone.0140325.g002
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Within all four tissues studied, the largest differences were seen in the lymph node. Lymph
nodes are believed to be the first pertinent lymphoid tissues to be affected following Leishmania
dissemination from skin macrophages [24] in natural infection. Comparing controls to Group
1, transcription of all TLRs and cytokines observed was down regulated significantly with the
exception of TLR9. TLR2 has been associated with a protective role in a number of murine
models of leishmaniosis. In a L.majormurine model, the absence of TLR2 led to an increased
number of cutaneous lesions [43] and TLRs 2 and 3 were involved in the phagocytosis of L.
donovani parasites [44]. Most recently, it was reported that the macrophages derived from
peripheral blood from Leishmania infected dogs showed a decrease in TLR2 compared with
healthy non-infected dogs [45] in agreement with our findings.
There was a general trend of down regulation in the lymph nodes of these dogs as time pro-
gressed for all target genes with the exception of TLR2. TLR2 transcription was down regulated
in the early stages of infection and then increased between Groups 1 and 2. This correlates with
the silent establishment of infection that Leishmania is renowned for. A silent phase was
reported by Belkaid and colleagues in mice infected with L.major over a period of 4–5 weeks
before the development of lesions [46]. The silent phase in our study was further supported by
the down regulation of IL-22 transcription. The silent establishment was also reported in a dog
cytokine study where a low proportion of experimentally infected dogs expressed specific cyto-
kines in the first eight months of infection coupled with parasite dispersion, but without clini-
cal signs of disease [47]. The authors suggested that this was the parasite ‘silent establishment’
by avoiding adverse host-cell mediated immunological reactions [47]. Ehrchen and colleagues
demonstrated that mice lacking peripheral lymph nodes were more susceptible to L.major
infection and elicited a Th2 response [48]. This finding illustrated that lymph nodes are crucial
for assisting in the induction of a protective Th1 response. This could further explain the pro-
gressive onset of disease in the animals in this study.
The down regulation of TLR3 in the lymph node has also been associated with the establish-
ment of disease, as observed in the present study. TLR3 is reported to be needed for nitric
oxide production and parasite phagocytosis [44], therefore a down regulation in this TLR
would favour disease progression. Using a hamster model, Ives and colleagues demonstrated
that metastasizing L. guyanensis parasites have a high Leishmania RNA virus–1(LRV1) burden
which is recognized by the host TLR3 to induce pro-inflammatory cytokines and chemokines
and exacerbation of disease [49]. The absence of TLR4 in a knockout murine L.majormodel
resulted in increased cutaneous lesions [36] and treatment with TLR4 and TLR9 agonists less-
ened disease progression [38]. In the lymph node of the present study, TLR4 transcription was
down regulated in both infected groups compared with controls and TLR9 transcription was
down-regulated with disease progression. TLR9 deficient mice exhibited a deficit in lymph
node expansion following L.major infection and increased susceptibility [50]. The down regu-
lation of TLR3, TLR4, TLR9, IL-17 and IL-22 transcription seen between the infected groups in
our study are indicative of disease establishment.
In the skin, no significant changes were seen for TLR2, TLR3, TLR4, IL-17 or IL-22 between
any of the three groups studied. This supports the silent establishment of infection as reported
earlier. Only TLR9 was significantly up regulated in the early stages of infection and marginal
significance was revealed for FoxP3 when both Groups 1 and 2 were compared with controls.
The trend for down regulation of the TLRs with disease progression seen in this tissue is sug-
gestive of an inhibitory role where the parasite may be facilitating the onset of disease by reduc-
ing or limiting the transcription of these TLRs which would otherwise play a protective role.
Tuon and colleagues looked at the TLR9 expression in patients with CL caused by L. brazilien-
sis. The percentage of cells that expressed TLR9 was significantly higher in the skin of CL
patients compared to normal skin but TLR9 expression was down-regulated in keratinocytes of
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infected patients [39]. The exact reason for this difference is unclear but the authors speculated
that higher TLR9 in granulomas could possibly have been a mechanism of parasite control and
the avoidance of more generalized and widespread dermatitis [39]. In another human CL
study, Tolouei and colleagues recently reported that the mean relative gene expression and
membrane expression of TLR2 and TLR4 in the macrophages of patients with the healing form
of cutaneous lesions were significantly higher than patients with the non-healing form of lesion
[51]. These studies suggest that there is a distinct role for both these TLRs in the outcome of
CL lesion as a result of L.major infection [51].
Recently in a canine study, increased frequency and expression of TLR9 was associated with
a lower parasite load in the jejunum of L. infantum infected dogs, whereas the colon showed a
higher parasite load along with an increased frequency and expression of TLR2 [19]. These
results are similar to our findings and might suggest active innate immune and pro-inflamma-
tory responses due to the presence of high Leishmania parasite densities in infected tissues.
There are even fewer reports documenting TLR expression or transcription in the liver and
spleen, especially in dogs. A recent study in mice has shown that infection with L. infantum
resulted in the increased transcription of TLR2 and TLR4 and associated cytokines. At all time
points observed, animals had a higher TLR2 mRNA transcription in the spleen compared with
non-infected controls [52]. This increased transcription could have been due to an influx of
inflammatory cells into the spleen, in particular at the beginning of the infection, and a
decrease seen at the chronic stage of infection possibly due to partial control of the infection
[52]. In contrast, in the present study, TLR4 transcription was down regulated with infection
and disease progression as well as other TLRs and cytokines. It must be taken into consider-
ation that murine and canine L. infantum experimental and natural infections are very differ-
ent [6,53] as shown with the results of this study. Recently, Melo and colleagues reported
increased TLR2 and TLR4 expression in spleen which is opposite to our findings in this tissue
[42]. These differences could be due to the fact that the dogs in the Melo study were naturally
infected and disease progression would be slower and subject to different immunological
responses to the experimentally infected animals in the present study. In a human study,
Kumar et al reported significantly higher levels of mRNA encoding both TLR2 and TLR4 in
pre-treatment splenic aspirate samples but no changes to TLR9 between these groups during L.
donovani infection [54].
To the best knowledge of the authors, this is the first study of Th17 cytokines in several tis-
sues in dogs experimentally infected with L. infantum. In addition, very limited data is available
about these cytokines in other canine diseases [35]. Both of these Th17 cytokines decreased
with disease progression in the present study. A reduction of these cytokines was previously
reported in dogs with canine inflammatory bowel disease [35]. As with many other cytokines,
there have been conflicting reports, suggesting both a protective and pathological role for these
Th17 cytokines in both human and rodent leishmaniases.
In an experimental leishmaniasis model, Th17 cells were associated with tissue destruction.
Mice deficient in IL-17 suffered smaller lesions with lower neutrophil infiltration compared to
wild type mice, which showed no reduction in parasite load with increased IL-17 [13]. Studies
with murine models of L. braziliensis [55] and L. panamensis [56] infections showed that
lesional healing was associated with elevated IL-17 and IFN-γ whereas a report of human
muco-cutaneous leishmaniasis (ML) reported that IL-17 might be involved in ML pathogenesis
rather than cure [57].
Conversely, there have been a few studies in recent years that have suggested that Th17
cytokines may be associated with protection against leishmaniasis. Ghosh et al demonstrated
that administration of recombinant IL-17 and IL-23 caused a significant suppression of organ
parasite burden in mice with a marked generation of IFN-γ and nitric oxide. The effects of this
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therapy were much faster for IL-17 compared with IL-23 [58]. In a human kala-azar study, it
was reported that both IL-17 and IL-22 were associated with a protective role [59]. Along with
signature Th1 cytokines, IL-17 and IL-22 were found to have complementary roles in protec-
tion against kala-azar as it was postulated that a defect in Th17 induction could increase the
risk of kala-azar [59]. In the present study, progressive down regulation of IL-22 transcription
in all tissues and of IL-17 transcription in the lymph node suggests that these cytokines might
have a protective role for CanL. In a murine model, L. infantum was found to induce IL-17A
production which promoted the control of parasite replication by strengthening Th1 responses
[12]. More studies investigating the role of these Th17 cell cytokines in CanL would be required
to determine the precise role they play in this infection.
The transcription factor FoxP3 was also measured in this study. T regulatory cells are
believed to act to counteract inflammatory immune responses, often limiting tissue damage.
The absence of these cells has been linked to a number of autoimmune conditions [60]. In
human leishmaniasis, elevated intra-lesional FoxP3 and IL-10 were associated with unrespon-
siveness to treatment during L. amazonensis infection [61]. However, recently, Silva and col-
leagues reported an increase in IL-10 production by Treg cells in the spleens of dogs naturally
infected with L. infantum and suggested that this could be due to persistent immune activation
triggered by the infection process [20]. In our study, no significant changes were seen in the
spleen for this transcription factor.
In the present study, we report a significant reduction in FoxP3 transcription in the lymph
node with disease progression. The parasite burden in the lymph node was also increased
between the two infected groups and taken together these findings suggest that FoxP3 is
required to control the infection. A decreasing trend in FoxP3 transcription between infected
groups together with increasing parasite density between these groups in the skin also support
the notion that FoxP3 might be associated with a protective role in this infection. Figueiredo
and colleagues recently found that L. infantum infection in dogs increased the expression of
TGF-β, IFN-γ, TNF-α and FoxP3 in the jejunum and colon of dogs [19]. In the present study,
FoxP3 transcription significantly increased in the skin between controls and sub-clinical
(Group 1) animals, whereas in the lymph node, FoxP3 transcription significantly decreased
with disease progression suggesting that transcription can vary depending on the tissue sam-
pled. Menendez-Souza and colleagues conversely reported that lower levels of FoxP3 were
observed in the skin of sick dogs compared with sub-clinical dogs and this was negatively cor-
related with clinical progression [22]. There is very little information about the role of FoxP3 in
CanL but in murine studies with Leishmania donovani, it has been reported that FoxP3 medi-
ates L. donovani persistence in the liver of mice [62]. It is possible that that role of FoxP3 in
leishmaniasis differs depending on not only the causal Leishmania species but also on the tissue
studied and host species as demonstrated in this study.
It is well established that serum IgG levels measured using either crude Leishmania antigens
or recombinant proteins correlate strongly with disease severity in human leishmaniasis [63]
and in CanL [64,65]. In the present study, the total IgG increased significantly with disease pro-
gression. A marked increase in this immunoglobulin as seen here has been well documented
before [27,29,66]. IgA was also increased with disease progression as previously observed [29]
but in our study but this was not significant. Earlier studies have also indicated that IgA is
increased in sick infected dogs compared with healthy infected or non-infected dogs [26,67].
High concentrations of Leishmania-specific IgA have additionally been reported in human VL
patients [68] and tegumentary leishmaniasis [69].
Parasite burden in the different tissues varied in this study. Although not ideal, intravenous
inoculation is believed to be the best route to induce clinical illness because it allows the quick
spread of live parasites to different organs [6,29,70]. Following i.v. challenge, in comparison to
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the visceral organs, the skin is one of the last tissues to be invaded by the parasite. This has
been well documented in a hamster model [71] and also in dogs [72–74] and has been reiter-
ated in this study. Parasite density in infected skin increased progressively with disease progres-
sion by comparison of Groups 1 and 2 as expected, even though each group was only sampled
once. Repeated sampling of each individual animal would have been expected to yield more
detail. It was recently reported that a high parasite number in skin is a good predictor of infec-
tiousness [75]. This progression would be expected in natural infections where the disease
would be transmitted by sand-fly bite. Thus, a higher load in the skin in late infection would be
advantageous to promote transmission onto a new host. The reduced number of parasites per/
mg of tissue in the liver and spleen seen in this study is likely to be due to the fact that this was
not a longitudinal investigation and readings between animals varied. However, obtaining sam-
ples of visceral organs from the same animal at different time points would have been very dif-
ficult and not cost effective.
There are several limitations of the present study. Unfortunately, samples were only avail-
able from endpoint tissue samples at six and 15 months post infection. It was therefore not pos-
sible to evaluate innate responses at the time of experimental infection or correlate features of
these responses with disease development through a prospective longitudinal study. However,
evaluating innate immune responses at six and 15 months post infection is of relevance.
Although classically the fate of infection appears to depend on the adaptive immune response,
it is important to take into account that over time the parasites would continue to replicate and
chronically infect new cells and hence have an impact on innate immune responses as seen in
this study and interact with adaptive immune responses. In addition, it must be noted that the
sample sizes between groups were not evenly matched and that control dogs were of different
ages and gender to the infected dogs. Although not ideal, these samples provide a base line to
compare with the infected animals. The controls were from a non-endemic region and were of
the same breed. Due to the limited data that is presently available in in vivomodels of this kind,
the findings from this study are crucial to assist in the further understanding of the immune
responses associated with CanL.
The cytokines and TLR profiles in different compartments where L. infantum replicates
appear to have a varied effect on local parasite control. The data described in this study sheds
more light on the complex immune responses that develop within the dog to L. infantum infec-
tion as the parasite progresses through its life cycle. This is the first report to highlight fluctua-
tions in the transcription of TLRs, IL-17, IL-22 and FoxP3 in the liver, spleen, lymph node and
skin that associate with L. infantum infection in dogs. Future studies are still needed to clarify
these findings and perhaps put them into the context of a natural infection. The precise
immune responses that are capable of controlling this infection must be identified in order to
progress with development of preventative approaches and/or treatment regimes for this
disease.
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